SCHEMBL407392

SCHEMBL407392

Brc1ccc2c(c1)c1cc(Br)ccc1n2CCCNc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.58
WEE1 P30291 4/20 0.47
TSPO P30536 4/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
CHEK1 O14757 3/20 0.45
SIGMAR1 Q99720 1/20 0.45
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
ALOX15 P16050 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DRD3 P35462 1/20 0.40
DNMT1 P26358 1/20 0.40
EGFR P00533 1/20 0.39
SRC P12931 1/20 0.39
RXRA P19793 1/20 0.39
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
OPRM1 P35372 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19559304 0.96 DNM1 (0.56) DNM1WEE1TSPOALDH1A1MAPT
SCHEMBL16709572 0.92 DNM1 (0.51) DNM1WEE1TSPOALDH1A1MAPT
SCHEMBL410708 0.91 DNM1 (0.60) DNM1WEE1TSPOALDH1A1MAPT
SCHEMBL19559320 0.87 DNM1 (0.48) DNM1WEE1TSPOALDH1A1MAPT
SCHEMBL19559317 0.86 DNM1 (0.43) DNM1WEE1TSPOMAPTCHEK1
SCHEMBL17513942 0.85 TSPO (0.50) DNM1WEE1TSPOMAPTSIGMAR1
SCHEMBL19559326 0.83 TSPO (0.69) DNM1TSPOMAPTSIGMAR1SMN1; SMN2
SCHEMBL1696729 0.80 TSPO (0.56) DNM1TSPOMAPTSIGMAR1HTT
SCHEMBL411764 0.77 DNM1 (0.77) DNM1TSPOALDH1A1MAPTLMNA
SCHEMBL409523 0.77 DNM1 (0.77) DNM1TSPOALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US claimed
US-20170157092-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-08 US claimed
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2016-12-15 US claimed
US-20160206596-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-07-21 US claimed
US-20160206594-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-21 US claimed
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-10-15 US claimed
EP-2925129-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2015-10-07 EP claimed
US-20150057301-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-26 US claimed
US-20140343018-A1 Anti-depression Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2014-11-20 US claimed
WO-2014031125-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-02-27 WO claimed
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-18 US claimed
EP-2590647-A2 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2013-05-15 EP claimed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 US claimed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US claimed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO claimed
EP-2385829-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2011-11-16 EP claimed
US-8039041-B2 Electroluminescent devices with electrode protection CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) 2011-10-18 US claimed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US claimed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US claimed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 1086/4885WEE1 4725/4885TSPO 478/4885
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX DNM1 897/4885WEE1 3783/4885TSPO 2470/4885
US-20160206594-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 510/4885WEE1 4290/4885TSPO 826/4885
US-20150057301-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 625/4885WEE1 4424/4885TSPO 671/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 897/4885WEE1 3783/4885TSPO 2470/4885
US-20110015217-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 510/4885WEE1 4290/4885TSPO 826/4885
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF DNM1 510/4885WEE1 4290/4885TSPO 826/4885
US-20140343018-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885WEE1 3501/4885TSPO 2600/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 897/4885WEE1 3783/4885TSPO 2470/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 538/4885WEE1 4346/4885TSPO 794/4885
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF DNM1 510/4885WEE1 4290/4885TSPO 826/4885
US-20160206596-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885WEE1 3501/4885TSPO 2600/4885
US-20170157092-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885WEE1 3501/4885TSPO 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.